Roland Gordon-Beresford
Plus aucun poste en cours
Profil
Roland Gordon-Beresford worked as Director-IP & Regulatory Affairs at Celyad Oncology SA from 2012 to 2013.
He also worked as Chief Regulatory Affairs Officer at Novadip Biosciences SA. Dr. Gordon-Beresford holds a doctorate degree from Université Libre de Bruxelles.
Anciens postes connus de Roland Gordon-Beresford
Sociétés | Poste | Fin |
---|---|---|
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Conseiller Juridique Général | - |
CELYAD ONCOLOGY SA | Conseiller Juridique Général | - |
Formation de Roland Gordon-Beresford
Université Libre de Bruxelles | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
Entreprise privées | 1 |
---|---|
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Health Technology |